Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,342
Distinct drugs
373
Records naming a cancer
982
Dated in the last 12 months
179
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 44 | Sep 22, 2026 |
| EMA | EU | 461 | 246 | 386 | 75 | 20 | Sep 18, 2026 |
Data updated 2 days agoSource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Oct 23, 2015 | Nivolumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as OPDIVO (DIN 02446634) under ATC L01FF01 NIVOLUMAB. Indications are not published in the Drug Product Database — see… | DIN02446634 | approvedsource: Marketed | health-canada-dpd |
| Oct 23, 2015 | Nivolumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as OPDIVO (DIN 02446626) under ATC L01FF01 NIVOLUMAB. Indications are not published in the Drug Product Database — see… | DIN02446626 | approvedsource: Marketed | health-canada-dpd |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Sep 29, 2015 | Peginterferon Beta-1a | Health Canada CA | cancer not stated in this record | Marketed in Canada as PLEGRIDY (DIN 02444399) under ATC L03AB13 PEGINTERFERON BETA-1A. Indications are not published in the Drug Product… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Aug 21, 2015 | Ponatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as ICLUSIG (DIN 02437333) under ATC L01EA05 PONATINIB. Indications are not published in the Drug Product Database — see… | DIN02437333 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jul 23, 2015 | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-TEMOZOLOMIDE (DIN 02443554) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product… | DIN02443554 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jun 29, 2015 | Nintedanib | Health Canada CA | cancer not stated in this record | Marketed in Canada as OFEV (DIN 02443074) under ATC L01EX09 NINTEDANIB. Indications are not published in the Drug Product Database — see… | DIN02443074 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| May 28, 2015 | Irinotecan | Health Canada CA | cancer not stated in this record | Marketed in Canada as IRINOTECAN HYDROCHLORIDE INJECTION (DIN 02412187) under ATC L01CE02 IRINOTECAN. Indications are not published in the… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Apr 29, 2015 | Ceritinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as ZYKADIA (DIN 02436779) under ATC L01ED02 CERITINIB. Indications are not published in the Drug Product Database — see… | DIN02436779 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Mar 31, 2015 | Paclitaxel | Health Canada CA | cancer not stated in this record | Marketed in Canada as PACLITAXEL INJECTION USP (DIN 02320150) under ATC L01CD01 PACLITAXEL. Indications are not published in the Drug… | DIN02320150 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Feb 27, 2015 | Docetaxel | Health Canada CA | cancer not stated in this record | Marketed in Canada as DOCETAXEL INJECTION (DIN 02437031) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product… | DIN02437031 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jan 8, 2015 | Doxorubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as DOXORUBICIN HYDROCHLORIDE INJECTION, USP (DIN 02413973) under ATC L01DB01 DOXORUBICIN. Indications are not published… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 16, 2014 | Doxorubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as DOXORUBICIN INJECTION, BP (DIN 02381982) under ATC L01DB01 DOXORUBICIN. Indications are not published in the Drug… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Nov 28, 2014 | Obinutuzumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as GAZYVA (DIN 02434806) under ATC L01FA03 OBINUTUZUMAB. Indications are not published in the Drug Product Database —… | DIN02434806 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Oct 20, 2014 | Etoposide | Health Canada CA | cancer not stated in this record | Marketed in Canada as ETOPOSIDE INJECTION (DIN 02239961) under ATC L01CB01 ETOPOSIDE. Indications are not published in the Drug Product… | DIN02239961 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Sep 19, 2014 | Capecitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as ACH-CAPECITABINE (DIN 02426765) under ATC L01BC06 CAPECITABINE. Indications are not published in the Drug Product… | DIN02426765 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Aug 14, 2014 | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as METHOTREXATE INJECTION, USP (DIN 02417626) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jul 23, 2014 | Capecitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as SANDOZ CAPECITABINE (DIN 02421925) under ATC L01BC06 CAPECITABINE. Indications are not published in the Drug Product… | DIN02421925 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jun 26, 2014 | Gemcitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as GEMCITABINE FOR INJECTION, USP (DIN 02407310) under ATC L01BC05 GEMCITABINE. Indications are not published in the… | DIN |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.
| approvedsource: Marketed |
| health-canada-dpd |
| Sep 25, 2015 | Peginterferon Beta-1a | Health Canada CA | cancer not stated in this record | Marketed in Canada as PLEGRIDY (DIN 02444402) under ATC L03AB13 PEGINTERFERON BETA-1A. Indications are not published in the Drug Product… | DIN02444402 | approvedsource: Marketed | health-canada-dpd |
| Sep 10, 2015 | Ramucirumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as CYRAMZA (DIN 02443805) under ATC L01FG02 RAMUCIRUMAB. Indications are not published in the Drug Product Database —… | DIN02443805 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Jul 23, 2015 | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-TEMOZOLOMIDE (DIN 02443538) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product… | DIN02443538 | approvedsource: Marketed | health-canada-dpd |
| Jul 23, 2015 | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-TEMOZOLOMIDE (DIN 02443511) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product… | DIN02443511 | approvedsource: Marketed | health-canada-dpd |
| Jul 23, 2015 | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-TEMOZOLOMIDE (DIN 02443481) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product… | DIN02443481 | approvedsource: Marketed | health-canada-dpd |
| Jul 23, 2015 | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-TEMOZOLOMIDE (DIN 02443473) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product… | DIN02443473 | approvedsource: Marketed | health-canada-dpd |
| Jul 22, 2015 | Anastrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as ANASTROZOLE (DIN 02442736) under ATC L02BG03 ANASTROZOLE. Indications are not published in the Drug Product Database… | DIN02442736 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Jun 29, 2015 | Nintedanib | Health Canada CA | cancer not stated in this record | Marketed in Canada as OFEV (DIN 02443066) under ATC L01EX09 NINTEDANIB. Indications are not published in the Drug Product Database — see… | DIN02443066 | approvedsource: Marketed | health-canada-dpd |
| Jun 22, 2015 | Bicalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as VAN-BICALUTAMIDE (DIN 02428709) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product… | DIN02428709 | withdrawnsource: Cancelled Post Marketsince Aug 7, 2019 | health-canada-dpd |
| Jun 8, 2015 | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as VAN-LETROZOLE (DIN 02428156) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product Database… | DIN02428156 | withdrawnsource: Cancelled Post Marketsince Aug 7, 2019 | health-canada-dpd |
| Jun 8, 2015 | Anastrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as VAN-ANASTROZOLE (DIN 02427818) under ATC L02BG03 ANASTROZOLE. Indications are not published in the Drug Product… | DIN02427818 | withdrawnsource: Cancelled Post Marketsince Aug 7, 2019 | health-canada-dpd |
| Jun 1, 2015 | Pembrolizumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as KEYTRUDA (DIN 02441152) under ATC L01FF02 PEMBROLIZUMAB. Indications are not published in the Drug Product Database —… | DIN02441152 | withdrawnsource: Cancelled Post Marketsince Dec 4, 2019 | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Jan 19, 2022 |
| health-canada-dpd |
| May 26, 2015 | Imatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as PMS-IMATINIB (DIN 02431122) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database —… | DIN02431122 | withdrawnsource: Dormantsince May 16, 2018 | health-canada-dpd |
| May 26, 2015 | Imatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as PMS-IMATINIB (DIN 02431114) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database —… | DIN02431114 | withdrawnsource: Dormantsince Jul 24, 2020 | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Apr 21, 2015 | Idelalisib | Health Canada CA | cancer not stated in this record | Marketed in Canada as ZYDELIG (DIN 02438801) under ATC L01EM01 IDELALISIB. Indications are not published in the Drug Product Database — see… | DIN02438801 | approvedsource: Marketed | health-canada-dpd |
| Apr 21, 2015 | Idelalisib | Health Canada CA | cancer not stated in this record | Marketed in Canada as ZYDELIG (DIN 02438798) under ATC L01EM01 IDELALISIB. Indications are not published in the Drug Product Database — see… | DIN02438798 | approvedsource: Marketed | health-canada-dpd |
| Apr 15, 2015 | Ruxolitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as JAKAVI (DIN 02434814) under ATC L01EJ01 RUXOLITINIB. Indications are not published in the Drug Product Database — see… | DIN02434814 | approvedsource: Marketed | health-canada-dpd |
| Apr 10, 2015 | Doxorubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as DOXORUBICIN HYDROCHLORIDE INJECTION (DIN 02375710) under ATC L01DB01 DOXORUBICIN. Indications are not published in… | DIN02375710 | withdrawnsource: Cancelled Post Marketsince Apr 21, 2021 | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Mar 11, 2015 | Carboplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as CARBOPLATIN INJECTION BP (DIN 02320371) under ATC L01XA02 CARBOPLATIN. Indications are not published in the Drug… | DIN02320371 | approvedsource: Marketed | health-canada-dpd |
| withdrawnsource: Dormantsince Oct 29, 2025 |
| health-canada-dpd |
| Feb 3, 2015 | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as NAT-LETROZOLE (DIN 02421585) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product Database… | DIN02421585 | approvedsource: Marketed | health-canada-dpd |
| Feb 3, 2015 | Anastrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as NAT-ANASTROZOLE (DIN 02417855) under ATC L02BG03 ANASTROZOLE. Indications are not published in the Drug Product… | DIN02417855 | approvedsource: Marketed | health-canada-dpd |
| withdrawnsource: Dormantsince Jun 1, 2021 |
| health-canada-dpd |
| Jan 6, 2015 | Bortezomib | Health Canada CA | cancer not stated in this record | Marketed in Canada as BORTEZOMIB FOR INJECTION (DIN 02423405) under ATC L01XG01 BORTEZOMIB. Indications are not published in the Drug… | DIN02423405 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Dec 8, 2014 | Erlotinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-ERLOTINIB (DIN 02377713) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database… | DIN02377713 | approvedsource: Marketed | health-canada-dpd |
| Dec 8, 2014 | Erlotinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-ERLOTINIB (DIN 02377705) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database… | DIN02377705 | approvedsource: Marketed | health-canada-dpd |
| Dec 8, 2014 | Erlotinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-ERLOTINIB (DIN 02377691) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database… | DIN02377691 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Nov 19, 2014 | Ibrutinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as IMBRUVICA (DIN 02434407) under ATC L01EL01 IBRUTINIB. Indications are not published in the Drug Product Database —… | DIN02434407 | approvedsource: Marketed | health-canada-dpd |
| Nov 4, 2014 | Idarubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as IDARUBICIN (DIN 02410028) under ATC L01DB06 IDARUBICIN. Indications are not published in the Drug Product Database —… | DIN02410028 | approvedsource: Marketed | health-canada-dpd |
| withdrawnsource: Dormantsince Aug 3, 2017 |
| health-canada-dpd |
| Oct 1, 2014 | Fluorouracil | Health Canada CA | cancer not stated in this record | Marketed in Canada as FLUOROURACIL INJECTION USP (DIN 02413450) under ATC L01BC02 FLUOROURACIL. Indications are not published in the Drug… | DIN02413450 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Sep 19, 2014 | Capecitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as ACH-CAPECITABINE (DIN 02426757) under ATC L01BC06 CAPECITABINE. Indications are not published in the Drug Product… | DIN02426757 | approvedsource: Marketed | health-canada-dpd |
| withdrawnsource: Dormantsince Oct 4, 2024 |
| health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Jul 23, 2014 | Capecitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as SANDOZ CAPECITABINE (DIN 02421917) under ATC L01BC06 CAPECITABINE. Indications are not published in the Drug Product… | DIN02421917 | approvedsource: Marketed | health-canada-dpd |
| Jul 10, 2014 | Etoposide | Health Canada CA | cancer not stated in this record | Marketed in Canada as ETOPOSIDE INJECTION, USP (DIN 02422530) under ATC L01CB01 ETOPOSIDE. Indications are not published in the Drug… | DIN02422530 | withdrawnsource: Dormantsince Aug 12, 2020 | health-canada-dpd |
| Jul 2, 2014 | Paclitaxel | Health Canada CA | cancer not stated in this record | Marketed in Canada as PACLITAXEL INJECTION USP (DIN 02391465) under ATC L01CD01 PACLITAXEL. Indications are not published in the Drug… | DIN02391465 | approvedsource: Marketed | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince May 8, 2017 |
| health-canada-dpd |